TSFECG02:	Categorized Corrected QT Interval Values Over Time; Safety Analysis Set (Study jjcs - core)				
QTc Interval 	Active Study Agent 	Active Study Agent 	 	
  Study Visit 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
   Criteria, n (%) 	N=53 	N=73 	N=59 	
QT Interval, Corrected (msec) 	 	 	 	
Baseline 	 	 	 	
N 	53 	73 	59 	
≤450 	42 (79.2%) 	54 (74.0%) 	42 (71.2%) 	
>450 to ≤480  	5 (9.4%) 	10 (13.7%) 	8 (13.6%) 	
>480 to ≤500 	3 (5.7%) 	3 (4.1%) 	3 (5.1%) 	
>500 	3 (5.7%) 	6 (8.2%) 	6 (10.2%) 	
 	 	 	 	
Month 1 	 	 	 	
N 	53 	71 	58 	
≤450 	43 (81.1%) 	50 (70.4%) 	42 (72.4%) 	
>450 to ≤480  	5 (9.4%) 	2 (2.8%) 	8 (13.8%) 	
>480 to ≤500 	1 (1.9%) 	7 (9.9%) 	3 (5.2%) 	
>500 	4 (7.5%) 	12 (16.9%) 	5 (8.6%) 	
 	 	 	 	
Month 3 	 	 	 	
N 	53 	53 	56 	
≤450 	40 (75.5%) 	37 (69.8%) 	46 (82.1%) 	
>450 to ≤480  	4 (7.5%) 	6 (11.3%) 	5 (8.9%) 	
>480 to ≤500 	2 (3.8%) 	3 (5.7%) 	3 (5.4%) 	
>500 	7 (13.2%) 	7 (13.2%) 	2 (3.6%) 	
 	 	 	 	
Month 6 	 	 	 	
N 	51 	47 	51 	
≤450 	36 (70.6%) 	35 (74.5%) 	43 (84.3%) 	
>450 to ≤480  	9 (17.6%) 	3 (6.4%) 	2 (3.9%) 	
>480 to ≤500 	3 (5.9%) 	3 (6.4%) 	1 (2.0%) 	
>500 	3 (5.9%) 	6 (12.8%) 	5 (9.8%) 	
 	 	 	 	
Month 9 	 	 	 	
N 	41 	42 	51 	
≤450 	31 (75.6%) 	32 (76.2%) 	41 (80.4%) 	
>450 to ≤480  	4 (9.8%) 	4 (9.5%) 	4 (7.8%) 	
>480 to ≤500 	1 (2.4%) 	2 (4.8%) 	3 (5.9%) 	
>500 	5 (12.2%) 	4 (9.5%) 	3 (5.9%) 	
 	 	 	 	
Month 12 	 	 	 	
N 	37 	35 	48 	
≤450 	25 (67.6%) 	26 (74.3%) 	35 (72.9%) 	
>450 to ≤480  	4 (10.8%) 	4 (11.4%) 	5 (10.4%) 	
>480 to ≤500 	2 (5.4%) 	1 (2.9%) 	4 (8.3%) 	
>500 	6 (16.2%) 	4 (11.4%) 	4 (8.3%) 	
 	 	 	 	
QTcB Interval, Aggregate (msec) 	 	 	 	
Baseline 	 	 	 	
N 	53 	73 	59 	
≤450 	37 (69.8%) 	58 (79.5%) 	46 (78.0%) 	
>450 to ≤480  	4 (7.5%) 	8 (11.0%) 	4 (6.8%) 	
>480 to ≤500 	5 (9.4%) 	3 (4.1%) 	4 (6.8%) 	
>500 	7 (13.2%) 	4 (5.5%) 	5 (8.5%) 	
 	 	 	 	
Month 1 	 	 	 	
N 	53 	71 	58 	
≤450 	38 (71.7%) 	60 (84.5%) 	41 (70.7%) 	
>450 to ≤480  	8 (15.1%) 	3 (4.2%) 	10 (17.2%) 	
>480 to ≤500 	4 (7.5%) 	5 (7.0%) 	3 (5.2%) 	
>500 	3 (5.7%) 	3 (4.2%) 	4 (6.9%) 	
 	 	 	 	
Month 3 	 	 	 	
N 	53 	53 	56 	
≤450 	41 (77.4%) 	38 (71.7%) 	47 (83.9%) 	
>450 to ≤480  	6 (11.3%) 	4 (7.5%) 	4 (7.1%) 	
>480 to ≤500 	2 (3.8%) 	6 (11.3%) 	2 (3.6%) 	
>500 	4 (7.5%) 	5 (9.4%) 	3 (5.4%) 	
 	 	 	 	
Month 6 	 	 	 	
N 	51 	47 	51 	
≤450 	37 (72.5%) 	40 (85.1%) 	42 (82.4%) 	
>450 to ≤480  	6 (11.8%) 	2 (4.3%) 	3 (5.9%) 	
>480 to ≤500 	5 (9.8%) 	3 (6.4%) 	3 (5.9%) 	
>500 	3 (5.9%) 	2 (4.3%) 	3 (5.9%) 	
 	 	 	 	
Month 9 	 	 	 	
N 	41 	42 	51 	
≤450 	33 (80.5%) 	33 (78.6%) 	41 (80.4%) 	
>450 to ≤480  	4 (9.8%) 	5 (11.9%) 	3 (5.9%) 	
>480 to ≤500 	2 (4.9%) 	1 (2.4%) 	4 (7.8%) 	
>500 	2 (4.9%) 	3 (7.1%) 	3 (5.9%) 	
 	 	 	 	
Month 12 	 	 	 	
N 	37 	35 	48 	
≤450 	33 (89.2%) 	29 (82.9%) 	37 (77.1%) 	
>450 to ≤480  	1 (2.7%) 	3 (8.6%) 	8 (16.7%) 	
>480 to ≤500 	2 (5.4%) 	2 (5.7%) 	1 (2.1%) 	
>500 	1 (2.7%) 	1 (2.9%) 	2 (4.2%) 	
 	 	 	 	
QTcF Interval, Aggregate (msec) 	 	 	 	
Baseline 	 	 	 	
N 	53 	73 	59 	
≤450 	44 (83.0%) 	59 (80.8%) 	42 (71.2%) 	
>450 to ≤480  	2 (3.8%) 	6 (8.2%) 	9 (15.3%) 	
>480 to ≤500 	4 (7.5%) 	2 (2.7%) 	5 (8.5%) 	
>500 	3 (5.7%) 	6 (8.2%) 	3 (5.1%) 	
 	 	 	 	
Month 1 	 	 	 	
N 	53 	71 	58 	
≤450 	42 (79.2%) 	57 (80.3%) 	49 (84.5%) 	
>450 to ≤480  	3 (5.7%) 	8 (11.3%) 	1 (1.7%) 	
>480 to ≤500 	5 (9.4%) 	2 (2.8%) 	2 (3.4%) 	
>500 	3 (5.7%) 	4 (5.6%) 	6 (10.3%) 	
 	 	 	 	
Month 3 	 	 	 	
N 	53 	53 	56 	
≤450 	42 (79.2%) 	40 (75.5%) 	43 (76.8%) 	
>450 to ≤480  	3 (5.7%) 	4 (7.5%) 	2 (3.6%) 	
>480 to ≤500 	6 (11.3%) 	4 (7.5%) 	5 (8.9%) 	
>500 	2 (3.8%) 	5 (9.4%) 	6 (10.7%) 	
 	 	 	 	
Month 6 	 	 	 	
N 	51 	47 	51 	
≤450 	42 (82.4%) 	37 (78.7%) 	36 (70.6%) 	
>450 to ≤480  	4 (7.8%) 	2 (4.3%) 	7 (13.7%) 	
>480 to ≤500 	2 (3.9%) 	1 (2.1%) 	3 (5.9%) 	
>500 	3 (5.9%) 	7 (14.9%) 	5 (9.8%) 	
 	 	 	 	
Month 9 	 	 	 	
N 	41 	42 	51 	
≤450 	32 (78.0%) 	36 (85.7%) 	38 (74.5%) 	
>450 to ≤480  	2 (4.9%) 	1 (2.4%) 	3 (5.9%) 	
>480 to ≤500 	3 (7.3%) 	3 (7.1%) 	4 (7.8%) 	
>500 	4 (9.8%) 	2 (4.8%) 	6 (11.8%) 	
 	 	 	 	
Month 12 	 	 	 	
N 	37 	35 	48 	
≤450 	30 (81.1%) 	27 (77.1%) 	38 (79.2%) 	
>450 to ≤480  	2 (5.4%) 	4 (11.4%) 	7 (14.6%) 	
>480 to ≤500 	3 (8.1%) 	0 	2 (4.2%) 	
>500 	2 (5.4%) 	4 (11.4%) 	1 (2.1%) 	

Note: N is the number of subjects with a non-missing value for the ECG parameter at the specified time point. 	
Note: N is the number of subjects with a non-missing value for the ECG parameter at the specified time point.	
Note: N is the number of subjects with a non-missing value for the ECG parameter at the specified time point.	
Note: N is the number of subjects with a non-missing value for the ECG parameter at the specified time point.